The
global meningococcal vaccines market is expected to grow moderately over the
forecast period. Meningococcal disease is a possibly lethal illness caused by a
bacterium called Neisseria meningitides. This bacterium is recognized for
causing serious infection in the meninges, which are thin layers of connective
tissues adjoining the spinal cord and brain. This disease occurs at irregular
intervals all over the world with seasonal variations. It accounts for a part
of endemic bacterial meningitis that advances quickly causing death within 24
hours from the commencement of symptoms.
Common
medical symptoms of meningococcal disease include bacteremia, pneumonia, and
meningitis. Other less common symptoms are pericarditis or endocarditis,
conjunctivitis, pharyngitis, cervicitis, myocarditis, arthritis, and
urethritis. Symptoms related to this disease include neck stiffness, nausea,
lethargy, petechial rashes, high fever, confusion, and vomiting. Meningococcal
vaccines are used for curing meningitis caused by bacterium Neisseria
meningitides. Formerly, there were no cautionary measures existing to avoid
meningitis and nutrient supplements along with antibiotics were used for the
treatment of this disease. These vaccines are also used for treating
septicemia, pneumonia, meningitis, and meningococcemia. It can be categorized
based on their immunologic reactivity. Presently, the global meningococcal
vaccines are of four types which include bivalent (serogroup A and C),
tetravalent (serogroup A, C, Y, and W-135), polysaccharide based, and trivalent
(serogroup A, C, and W-135).
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/meningococcal-vaccines-market
There
is, presently, only a single vaccine available for serogroup B in the U.S.,
even though it accounted for more than one-third of the diseases cases in the
country. The components and nature of the vaccines are heat-stable, purified,
lyophilized capsular polysaccharides derivative of the meningococci of the
corresponding serogroups. The major factor driving the growth of global
meningococcal vaccines market includes the growing occurrence of meningitis
across the globe. Growing awareness about the diseases and their vaccines is
also driving the overall market. Other factors responsible for the growth of
the market include several public-private partnerships for carrying out
research & development activities, manufacturing quality vaccines at
affordable prices, and the presence of vaccines in a pipeline and their
expected commercialization. Additionally, rising government interventions in
refining healthcare infrastructure, numerous awareness programs, and
incorporation of security guidelines concerning meningococcal vaccines are also
projected to positively impact the global meningococcal vaccines market. The
introduction of advanced serotype B vaccines from large global drug makers
including Pfizer and Novartis further boosts the demand.
However,
factors restraining the growth of the global meningococcal vaccines market
include rising financial severity in the European region, serotype mismatch and
less than optimum coverage across countries. A delay in accessing the disease
epidemiology over regular intervals because of cost issues is expected to
negatively impact the overall market in the developing countries. The prime
barrier of the market includes the maintenance of cold chain for the delivery
of vaccines leads to rising in the cost of vaccination. Other factors such as
high cost of vital vaccines, including Bexsero and the requirement for
effective cold chain logistics to maintain efficacy, price wars for vaccines
from equivalent drug makers that could eradicate the customer base and safety
of the vaccines may also hinder the growth of the global meningococcal vaccines
market.
North
America emerged as the regional leader of the global meningococcal vaccines
market on account of rising government prevention & intervention programs,
and research & development activities by numerous manufacturers. The
increased awareness about the health care facilities is responsible for the
growth in the region. The majority of the revenue was generated by the U.S. in
North America. However, Asia-Pacific meningococcal vaccines market is projected
to have the highest growth rate in the market over the next eight years. This
high growth rate can be attributed to factors such as increased spending on
health care and low manufacturing costs. China, India, and Japan are estimated
to be the most rapidly growing meningococcal vaccines market in Asia-Pacific.
Some
of the key meningococcal vaccines industry participants include Neuron Biotech,
Pfizer Inc., Sanofi S.A., Biomed Pvt. Ltd., Serum Institute of India Ltd.,
Baxter International, Novartis International AG, JN-International Medical
Corporation, and GlaxoSmithKline Plc. Novartis International AG, GSK Plc., and
Sanofi S.A. together account for more than 90% of the global market. Presently,
Pfizer is also working towards generating a vaccine named MnBrLP2086. This vaccine
is under clinical trial phase III and has been granted the breakthrough therapy
by FDA.
Request a Free Sample Copy
of This Report @ https://www.millioninsights.com/industry-reports/meningococcal-vaccines-market/request-sample
Comments
Post a Comment